Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Sinovac Quadrivalent Influenza Vaccine in Children Aged 3-8 Years
NCT04997239Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Oct 2021
- Primary completion
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of TetrAnflu in seasonal influenza, sponsored by Sinovac Biotech Ltd.. Started Oct 2021; status: completed.
02
Drugs
TetrAnflu
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT04997239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997239.